Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight Subjects Clear all
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

NCT03787225
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

NCT02307279
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Gelesis100, placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
25
States / cities
Anaheim, California • San Diego, California • Tustin, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111
View directory record Official record
Conditions
Diabetes
Interventions
CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

NCT01818921
View directory record Official record
Conditions
Obesity, Over-weight, Prader-Willi Syndrome
Interventions
ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Semaglutide in CFRD

NCT05788965
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voriconazole in Obese Subjects

NCT01030653
View directory record Official record
Conditions
Healthy
Interventions
Voriconazole low dose, Voriconazole high dose
Drug
Lead sponsor
Manjunath Prakash Pai
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
3-V Bioscience-2640
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
35 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects

NCT01656681
View directory record Official record
Conditions
Obesity
Interventions
THIAA, Placebo
Dietary Supplement
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

NCT04167553
View directory record Official record
Conditions
Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions
HM15136, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Brain Blood Flow and Lactate in Non-obese and Obese Subjects

NCT06791837
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
EXERCISE
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

NCT03486392
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Liraglutide, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations

NCT00487344
View directory record Official record
Conditions
Obesity
Interventions
Non-Personalized Meal Planning, Personalized Meal Planning and Dietetic Consultation
Procedure
Lead sponsor
Central FITT, Inc
Other
Eligibility
25 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Edmond, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

NCT00474630
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed Not applicable Interventional

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

NCT03058029
View directory record Official record
Conditions
Overweight, Diabetes, PreDiabetes, Obesity
Interventions
Gelesis200, Placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

NCT05035095
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Anniston, Alabama • Fresno, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

NCT03139305
View directory record Official record
Conditions
Obesity
Interventions
Glucagon, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

NCT03574584
View directory record Official record
Conditions
Metabolism and Nutrition Disorders, Overweight or Obesity
Interventions
NNC0165-1562, Semaglutide, Placebo (NNC0165-1562)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
19 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Placebo for ABBV-295
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 6:55 PM EDT